Higher Level of Dickkopf-1 is Associated with Low Bone Mineral Density and Higher Prevalence of Vertebral Fractures in Patients with Ankylosing Spondylitis.

scientific article

Higher Level of Dickkopf-1 is Associated with Low Bone Mineral Density and Higher Prevalence of Vertebral Fractures in Patients with Ankylosing Spondylitis. is …
instance of (P31):
scholarly articleQ13442814

External links are
P6179Dimensions Publication ID1025729210
P356DOI10.1007/S00223-015-0093-3
P698PubMed publication ID26645432

P50authorVidya KunnathullyQ41067714
Maurizio RossiniQ41067734
davide gattiQ58150575
Luca IdolazziQ58348555
Francesco GhellereQ85932366
Silvano AdamiQ114314176
P2093author name stringElena Fracassi
Ombretta Viapiana
Maria Rosaria Povino
Sonila Troplini
P2860cites workThe role of the Wnt-signaling antagonist DKK1 in the development of osteolytic lesions in multiple myelomaQ28236113
Bone density, ultrasound measurements and body composition in early ankylosing spondylitisQ30700518
Bone mass is inversely proportional to Dkk1 levels in miceQ33834902
Evaluation of diagnostic criteria for ankylosing spondylitis. A proposal for modification of the New York criteriaQ34055060
Assessment of outcome in ankylosing spondylitis: an extended radiographic scoring systemQ35554631
Osteoimmunology and osteoporosisQ35840701
The epidemiology of osteoporosis and fractures in ankylosing spondylitisQ36111291
Osteoporosis in ankylosing spondylitis - prevalence, risk factors and methods of assessmentQ36245947
High prevalence of low bone mineral density in patients within 10 years of onset of ankylosing spondylitis: a systematic reviewQ36353404
Increased occurrence of spinal fractures related to ankylosing spondylitis: a prospective 22-year cohort study in 17,764 patients from a national registry in SwedenQ36608425
Low sclerostin levels: a predictive marker of persistent inflammation in ankylosing spondylitis during anti-tumor necrosis factor therapy?Q36633205
Osteoporosis and vertebral fractures in ankylosing spondylitisQ36841353
Excessive bone formation in a mouse model of ankylosing spondylitis is associated with decreases in Wnt pathway inhibitorsQ36907665
Serum dickkopf-1 level in postmenopausal females: correlation with bone mineral density and serum biochemical markersQ37009964
Role of sclerostin in bone and cartilage and its potential as a therapeutic target in bone diseasesQ37640833
Bone microarchitecture in ankylosing spondylitis and the association with bone mineral density, fractures, and syndesmophytesQ37690384
Osteoporosis in inflammatory joint diseasesQ37765505
Involvement of WNT/β-catenin signaling in the treatment of osteoporosis.Q38113112
Osteocyte control of bone remodeling: is sclerostin a key molecular coordinator of the balanced bone resorption-formation cycles?Q38230277
EULAR recommendations for the use of imaging in the diagnosis and management of spondyloarthritis in clinical practice.Q38402703
Dkk1-mediated inhibition of Wnt signaling in bone results in osteopeniaQ42801302
Incidence of vertebral fracture in europe: results from the European Prospective Osteoporosis Study (EPOS).Q43446741
Prevalence and annual incidence of vertebral fractures in patients with ankylosing spondylitisQ43947707
Bisphosphonates vs infliximab in ankylosing spondylitis treatment.Q44230212
Bone turnover markers, anterior pituitary and gonadal hormones, and bone mass evaluation using quantitative computed tomography in ankylosing spondylitisQ45183754
Ankylosing spondylitis is associated with an increased risk of vertebral and nonvertebral clinical fractures: a population-based cohort study.Q45250384
Vertebral fracture assessment using a semiquantitative technique.Q45969757
Prevalence and risk factors of osteoporosis and vertebral fractures in patients with ankylosing spondylitisQ47799974
Developmental regulation of Wnt/beta-catenin signals is required for growth plate assembly, cartilage integrity, and endochondral ossification.Q52055378
Dickkopf-1 level is lower in patients with ankylosing spondylitis than in healthy people and is not influenced by anti-tumor necrosis factor therapy.Q53411277
Ankylosing spondylitis and bone mineral density--what is the ideal tool for measurement?Q53604351
Ankylosing spondylitis and the risk of fracture: results from a large primary care-based nested case-control studyQ57086718
Biomarkers of Bone Metabolism in Ankylosing Spondylitis in Relation to Osteoproliferation and OsteoporosisQ57623454
Vertebral Fractures in Ankylosing Spondylitis Are Associated with Lower Bone Mineral Density in Both Central and Peripheral SkeletonQ57623464
Low circulating Dickkopf-1 and its link with severity of spinal involvement in diffuse idiopathic skeletal hyperostosisQ57752499
P433issue5
P407language of work or nameEnglishQ1860
P304page(s)438-445
P577publication date2015-12-08
P1433published inCalcified Tissue InternationalQ5018771
P1476titleHigher Level of Dickkopf-1 is Associated with Low Bone Mineral Density and Higher Prevalence of Vertebral Fractures in Patients with Ankylosing Spondylitis
P478volume98

Reverse relations

cites work (P2860)
Q37315396Anti-citrullinated protein antibodies and high levels of rheumatoid factor are associated with systemic bone loss in patients with early untreated rheumatoid arthritis
Q47723896In psoriatic arthritis Dkk-1 and PTH are lower than in rheumatoid arthritis and healthy controls
Q92358423Low Serum Levels of DKK2 Predict Incident Low-Impact Fracture in Older Women
Q89563793Parathyroid hormone is a determinant of serum Dickkopf-1 levels in ankylosing spondylitis
Q33695718Serum Sclerostin Levels in Patients with Ankylosing Spondylitis and Rheumatoid Arthritis: A Systematic Review and Meta-Analysis
Q55008112Serum Sclerostin as a Possible Biomarker in Ankylosing Spondylitis: A Case-Control Study.
Q38921875The Utility of Biomarkers in Osteoporosis Management.